{"name":"Savara Inc.","slug":"savara-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Vancomycin inhalation powder","genericName":"Vancomycin inhalation powder","slug":"vancomycin-inhalation-powder","indication":"Treatment of nontuberculous mycobacterial lung disease","status":"phase_3"},{"name":"Antimycobacterial regimen","genericName":"Antimycobacterial regimen","slug":"antimycobacterial-regimen","indication":"Treatment of pulmonary nontuberculous mycobacterial disease","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"AeroVanc","genericName":"AeroVanc","slug":"aerovanc","indication":"Treatment of methicillin-resistant Staphylococcus aureus (MRSA)","status":"phase_1"},{"name":"Molgramostim nebulizer solution","genericName":"Molgramostim nebulizer solution","slug":"molgramostim-nebulizer-solution","indication":"Other","status":"phase_2"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Molgramostim Open-label","genericName":"Molgramostim Open-label","slug":"molgramostim-open-label","indication":"Pulmonary alveolar proteinosis (PAP)","status":"phase_3"}]}],"pipeline":[{"name":"Vancomycin inhalation powder","genericName":"Vancomycin inhalation powder","slug":"vancomycin-inhalation-powder","phase":"phase_3","mechanism":"Vancomycin inhalation powder works by inhibiting bacterial cell wall synthesis.","indications":["Treatment of nontuberculous mycobacterial lung disease"],"catalyst":""},{"name":"AeroVanc","genericName":"AeroVanc","slug":"aerovanc","phase":"phase_1","mechanism":"Aeruginibactin antibiotic","indications":["Treatment of methicillin-resistant Staphylococcus aureus (MRSA)"],"catalyst":""},{"name":"Antimycobacterial regimen","genericName":"Antimycobacterial regimen","slug":"antimycobacterial-regimen","phase":"phase_2","mechanism":"Antimycobacterial regimen works by inhibiting the growth of Mycobacterium tuberculosis.","indications":["Treatment of pulmonary nontuberculous mycobacterial disease"],"catalyst":""},{"name":"Molgramostim Open-label","genericName":"Molgramostim Open-label","slug":"molgramostim-open-label","phase":"phase_3","mechanism":"Molgramostim is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) that stimulates the production and activation of granulocytes and macrophages to enhance immune function.","indications":["Pulmonary alveolar proteinosis (PAP)"],"catalyst":""},{"name":"Molgramostim nebulizer solution","genericName":"Molgramostim nebulizer solution","slug":"molgramostim-nebulizer-solution","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxPNXdMQ2psWGdRVmMtU1pCSWhrLTdfZlZBTnVPaUJCNHVjSzYzQWdIaE0zcXp1Tl9VQnRhdlItS0dXblEzb3VieWtuRlhzMUpvSEF6MDVXSzZZMmRMb1ZuYWJmTEc2Z2lITS1jaEtWZzhwcGJpOUJ5ZDlDU1QxNnk1SXNqVHhYTi1XS01SYTRra3c2MWhMTXF0WEtpOF95T3MtSzBsUUZlTDdsLXlXZXhEWnA4Sm9zVzZUR3dTRHhFRGZYMVZ1cmxoaw?oc=5","date":"2026-03-04","type":"pipeline","source":"Business Wire","summary":"Savara Announces Participation in 2026 Citizens Life Sciences Conference - Business Wire","headline":"Savara Announces Participation in 2026 Citizens Life Sciences Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgJBVV95cUxPc01VTVdMWjNOXy0xaXJvTktvbFB2VF9UY04tNWpyLU8wWlB0UXlpSDF6NUZfS09STF80TkttbWNkbWJWYVdXNkxlSmV2WWF0bGtjRlRZZ1RxRlBhd2hzQXU4ZHZpeWFld3VUYTNqdE0wdktHUXZjV1VnWHp0eWJxTFB3aVBsRGlXZUVqdXl3YWpYMWVpWmJrM0FuLU52WlRsVFgtNlhvbkhib0pwSnNkSmRPeWtHWk5tWjhYbnRzZW5wMzBuYmRWS2U4ZUhhV0J4N2lHNzZrMW5fU0dJdE5CZmFHWlU3VVUtRFpxUGNzM2xuOVF0OWl2VFlrSGtWSzlUMm13d1A0ZGxROTZwbXlyRmw1dUJzWnh3bENEZVozZVBCYzhMajRyeGxCYXJZMVdMeTZmM2psQjMzUGVVWmVPcks4UUM4R3FFdXA5c0hB?oc=5","date":"2026-02-20","type":"regulatory","source":"Business Wire","summary":"Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire","headline":"Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOOEcxVWhKeTBOV1h0RmxzU1pJMjdGeGlyemtWZU5Oczc5d3N4RHVzcTdOWUo2aWxLY2d4U3dTaW00ZjM4RDRyeGY3Rll5VGpkMEk1bjExbTEwSTRURGRrVmFHa0JEbzkwUmZaazBhTUxCTnNaTVZWS3NKc2txSl9BM3h5N1hNV0tSb0I4bmx0OXd1QXhaczJwQzktMS1VYi1GTDN4aW9LbVY?oc=5","date":"2026-02-13","type":"pipeline","source":"Business Wire","summary":"Savara Announces New Employment Inducement Grant - Business Wire","headline":"Savara Announces New Employment Inducement Grant","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQMXlZdVA1UFVPUW85M1RyeExDRnJaLV8xc082NG55cXVjU3F1OFBPUVY5UVBmVjFBdjBZTWtUcGlsZVNtTVdZX3QxRHIydy1pcTdqOHRHcU42NDEwejNQdWVrVWJiUjNRaEFQTTF4VnpiTnQ0UGhfWFFwVGhlWGQ4dVd2N0ktVnQ3U1NodTFpaDZKMFkyLWpiZFM3clhsUTlyczlsRTNVVGl3bmctMzBSVVRmeVpwdUd4SkNLeXhjQ2JwTHd2NE5QcENVWQ?oc=5","date":"2026-02-04","type":"pipeline","source":"Business Wire","summary":"Savara Announces Participation in Upcoming Investor Healthcare Conferences - Business Wire","headline":"Savara Announces Participation in Upcoming Investor Healthcare Conferences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxQMU5tVmEtR0ljMVVlTUx1RkM5dmtDUFVFZmcxV0ZZNW9xbjRBakY4dVBHMDNtYWR3czJ5THdoVnhZaG9ibVVVSlRYUklxeFY3OGVJV1ZHMWhLVGhCbGpEd0VJT25JMXpvZEstQ1dMUW9RQnIybmQtUzhIcUhsYVN0bm1ndw?oc=5","date":"2026-01-08","type":"pipeline","source":"Yahoo Finance","summary":"PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI* - Yahoo Finance","headline":"PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPZjZUUXBLNEMxUnIxR2tBVXpxYWtfWUw1M3pVVnY2ZnRleHNOZXg2VE80SF9jcWpUTnBZV2pQeTNfWVZxTElPUWlZc29WY2daOS1XMGFpOTA3OXdocDB5THpJb1luMmlyUk1tQkZ4UU9YbWw0WnZFTndmTWZEUmk5N1NwcDVOT1RFMXJ6TjFiRzJiRFVINUpFaTNxU3JPNElsUzJNLUhGUmRUVmFjd0M3Mg?oc=5","date":"2025-12-28","type":"pipeline","source":"MyChesCo","summary":"Savara Heads to JPMorgan Conference as Investors Watch Rare Lung Drug - MyChesCo","headline":"Savara Heads to JPMorgan Conference as Investors Watch Rare Lung Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxQU3hQNWlSV3NHTUNnN1R1Um1POV91M2FNS1hyaXJIUzNIRTdLVzVZMDRVTDhjVWp0Uy1fX3RnUF9ma0VpcFhYX242ejBKaXBmR0VKcjgwdUdyTWJwSE85UUxwQjAzVHh4RjU4c29UQTZBWTdleUFmcWl5YlhTazhNOTMyNGFFXzYtNC1YeEU2NmhnVklTVUoxcnRFcjI3WDhpZF9RX0RCTnp1aUlhSVQ5RHgzelNWZ0NNQlZobFdoZU8yNWkyOXZjN1AyUGpJVzdHWEdiQTR6ZUJ3NWZXaklQNlRUMFBvQm5CR2lrLUNLTVNiYTVZYXVCb1VSYlo4ajVpYkp4d0xZeW9zQkZfUXpyMlFn?oc=5","date":"2025-12-03","type":"patent","source":"BioSpace","summary":"Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System - BioSpace","headline":"Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprieta","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE0ydnVjRklUSUdoQ05CNEdULTF4Sk01TlpUenk3cGpOY24xM3p5dzZ3blMxa0dSbHFrWTV5S2JUVDlPblpHdFljUmR0MGVyTnNqaVV1cmJPd2lUQVFZR0FHMjFUQzU0aWw5QzZiNjlMbEc2ZmpJMG1xUA?oc=5","date":"2025-11-16","type":"pipeline","source":"seekingalpha.com","summary":"Savara Stock: A High-Risk Opportunity (NASDAQ:SVRA) - seekingalpha.com","headline":"Savara Stock: A High-Risk Opportunity (NASDAQ:SVRA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPSXRMM0VPczExRHZjLW5hZFhSUUh5RG9VdERZRndRb3g0UjAwTzJFakVPdTVJMF9ZMTcydkRjRkxuWW41MzAzbjZaczgxdmF4OGFSbS13TjRrdXEwRWNQRVRIMzVhc3E2Sjd2YlZPMVhURWJoVHhBWUJtMFZ0WVF4dTNJVzR6QUZiWk5BLXRvM25oRHcyRndicXBnWkp6aGVQRzdRX2ln?oc=5","date":"2025-10-17","type":"pipeline","source":"Contract Pharma","summary":"Savara Promotes Dr. Yasmine Wasfi to Chief Medical Officer - Contract Pharma","headline":"Savara Promotes Dr. Yasmine Wasfi to Chief Medical Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNbDBwcENFaHBxaTVpZFFuQ1JwTjFXVGo0M2k5bHdlWmZHV3paZkJPQjloQ3RKUDEwS0JiYkNYblFnZlg4OFRydDRmanZ0RVlaOHBjM3NaOWpsVS1wbHRkLWFvNnhtMFM3SmY5NUdDTzBRVkFGWkFvT2tQTGxHTTdfUzAzSzVPZ3ZNY2dVQUxOM09zcmVudkxFTGg4dmRtQlgtcEJpUUtXWlg5aXgyQzBRRHkybjNFSGN6?oc=5","date":"2025-05-27","type":"regulatory","source":"Fierce Pharma","summary":"FDA calls for additional manufacturing data in refusal letter for Savara's respiratory asset - Fierce Pharma","headline":"FDA calls for additional manufacturing data in refusal letter for Savara's respiratory asset","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1oRHVPbTNoUG44Q3pKZERvZklGYmtMaXRWTFM3cXl1SklQU1czZDNwaHNNZUtmOWxjNzBVOXpxVVlNX1NWMERRR1EtUzFGV2phQzJR?oc=5","date":"2025-05-27","type":"regulatory","source":"FirstWord Pharma","summary":"Savara stock dives after FDA refuses filing for rare lung disease drug - FirstWord Pharma","headline":"Savara stock dives after FDA refuses filing for rare lung disease drug","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOdXROLVRDenRIb01VeldHVV9LTVdKMFc4SXdVMHRrdzkzeXllYmVvdXBFb29FVEF0S2lkc0JJaDd4YmxzZ2pXekNweFM4bWlvUDRWU19Fd1hoOG9aS3JXbk9PVkV5M2kyd2JLekpkQkdXOE9abTdfMjMtUVczTFZ4NVd5UUtvRG9abzIxRDhoLS1odw?oc=5","date":"2025-04-21","type":"pipeline","source":"seekingalpha.com","summary":"Savara: Make-It-Or-Break-It Molbreevi BLA Filing (NASDAQ:SVRA) - seekingalpha.com","headline":"Savara: Make-It-Or-Break-It Molbreevi BLA Filing (NASDAQ:SVRA)","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_3":2,"phase_1":1,"phase_2":2},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}